Supplementary Material for: Enfortumab vedotin-induced diabetic ketoacidosis and acute tubulointerstitial nephritis requiring intensive care in the treatment of advanced urothelial carcinoma: a case report

Enfortumab vedotin (EV) has been approved for the treatment of many types of cancer, and its use is still expanding. It is an essential drug used as a standard treatment for advanced and metastatic urothelial carcinoma, but is known to cause various adverse events. We report a patient with metastatic urothelial carcinoma who experienced multiple adverse events associated with diabetic ketoacidosis (DKA) during EV treatment. The onset of DKA during EV treatment has been reported to be associated with poor prognosis. Although strict management was required in the intensive care unit, we were able to save his life. We report on the pathogenesis and management of drug-induced diabetic ketoacidosis caused by EV based on our case and a literature review.